Welcome to our dedicated page for ImageneBio news (Ticker: IMA), a resource for investors and traders seeking the latest updates and insights on ImageneBio stock.
ImageneBio, Inc. develops therapeutics for immunological, autoimmune and inflammatory diseases, led by IMG-007, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life. News about IMA centers on clinical program updates for atopic dermatitis and alopecia areata, preclinical data presentations, research and development spending, and financial results.
The company’s updates also cover financing activity, including private placements and pre-funded warrants, as well as governance and compensation matters such as inducement grants and management appointments. ImageneBio was formed and funded through a completed reverse merger with Ikena Oncology and a concurrent private placement in 2025.
ImageneBio (IMA)/b) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, with CEO Kristin Yarema, Ph.D., representing the company.The fireside chat is scheduled for 3:30 p.m. ET and will be webcast and archived for 90 days on ImageneBio's investor relations events page. ImageneBio is a clinical-stage biotechnology company developing therapeutics for immunological, autoimmune and inflammatory diseases, led by its non-depleting anti-OX40 monoclonal antibody program, olevaprubart. Phase 1b/2a trials of olevaprubart in atopic dermatitis and alopecia areata have been completed, and a Phase 2b trial in moderate-to-severe atopic dermatitis is ongoing.
ImageneBio (Nasdaq: IMA) announced that its Board’s Compensation Committee granted inducement equity awards on August 14, 2026 under Nasdaq Listing Rule 5635(c)(4). These include 79,000 RSUs and 56,525 NSOs to three newly hired non‑executive employees and 65,000 RSUs and 56,000 NSOs to Chief Financial Officer Yanina Grant-Huerta, all under the 2025 Equity Inducement Plan. Ms. Grant-Huerta also received 39,000 RSUs under the 2025 Equity Incentive Plan. RSUs vest over four years using annual or 1‑year cliff plus quarterly schedules, while NSOs, priced at $5.84 per share, vest over four years with a 1‑year cliff and monthly vesting thereafter.
ImageneBio (Nasdaq: IMA) reported second quarter 2026 results and clinical updates for its lead asset, olevaprubart (IMG-007). Following a $30 million private placement in April, cash, cash equivalents and marketable securities totaled $136.2 million at June 30, 2026, which the company expects will fund planned operations into the first quarter of 2028.
The Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis is progressing under an amended protocol, with topline data anticipated in Q4 2027 and a long-term extension now enrolling. An Independent Data Monitoring Committee recommended the study proceed without changes, and no Kaposi sarcoma cases have been observed across the program as of July 31, 2026. A Phase 2 alopecia areata trial is planned to start in 2026, with initial data expected in 2028.
Q2 2026 R&D expenses were $6.7 million versus $5.7 million a year earlier, and G&A expenses were $5.1 million versus $1.7 million. Net loss was $10.2 million, or $0.63 per share, compared with a net loss attributable to common stockholders of $10.7 million, or $4.46 per share, in Q2 2025. Imagene also appointed Yanina Grant-Huerta as CFO and Matt Robbins as General Counsel.
ImageneBio (Nasdaq: IMA) appointed Matt Robbins as General Counsel, effective July 7, 2026. He brings over 15 years of corporate, securities, and transactional experience in life sciences.
Robbins will oversee legal, corporate governance, IP, and compliance as Imagene advances its lead candidate IMG-007 and scales Phase 2 programs in atopic dermatitis and alopecia areata.
ImageneBio (Nasdaq: IMA) announced that CEO Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 at 12:50 PM EDT. A live webcast and 90-day archive will be available on the Imagene investor relations website.
ImageneBio (Nasdaq: IMA) reported Q1 2026 results and an IMG-007 program update on May 7, 2026. The company closed a ~$30 million private placement in April, which the company says extends cash runway into Q1 2028. IMG-007 moves forward in a ~400-patient Phase 2b ADAPTIVE trial with topline data expected in Q4 2027; a Phase 2 alopecia areata study is planned for 2026 with initial data expected in 2028.
Imagene (NASDAQ: IMA) entered a definitive securities purchase agreement for a private placement expected to raise approximately $30 million in gross proceeds on April 13, 2026. Proceeds will support further development of IMG-007 in alopecia areata and late-stage development activities in moderate-to-severe atopic dermatitis.
Pursuant to the offering, Imagene is selling pre-funded warrants to purchase up to 5,770,335 shares at $5.199 per warrant, with an exercise price of $0.001 per share. The transaction is led by Coastlands Capital with participation from new and existing investors; Leerink Partners is sole placement agent.
ImageneBio (Nasdaq: IMA) announced inducement equity grants on March 16, 2026 to two newly hired employees under its 2025 Inducement Plan. The grants total 38,442 RSUs and 43,000 NSOs with NSO exercise price set at $6.20 per share.
The NSOs vest over four years (25% at one year, then monthly over 36 months). RSUs vest in equal annual installments over four years. Awards are subject to the 2025 Inducement Plan and individual award agreements.
ImageneBio (Nasdaq: IMA) reported Q4 and full-year 2025 results and provided program and corporate updates. Key highlights: IMG-007 Phase 2b ADAPTIVE trial is enrolling with topline data expected in 2027, >150 subjects dosed to date, and a favorable blinded safety review in March 2026. The company ended 2025 with $135.3M in cash and equivalents.
ImageneBio (NASDAQ: IMA) will participate in the 2026 Leerink Global Healthcare Conference in Miami, March 8-11. Management will join a fireside chat on March 10 at 3:00 PM EST and hold one-on-one meetings. A webcast will be available and archived for 90 days on the company events page.